产品编号 | bs-19565R |
英文名称 | OGFRL1 |
中文名称 | 阿片样物质生长因子受体样蛋白1抗体 |
别 名 | dJ331H24.1; Ogfrl1; OGRL1_HUMAN; Opioid growth factor receptor like 1; Opioid growth factor receptor-like protein 1. |
研究领域 | 肿瘤 细胞生物 神经生物学 信号转导 |
抗体来源 | Rabbit |
克隆类型 | Polyclonal |
交叉反应 | (predicted: Human,Mouse,Rat,Chicken,Pig,Cow,Horse,Rabbit,Sheep) |
产品应用 | IHC-P=1:100-500, IHC-F=1:100-500, ICC=1:100-500, IF=1:100-500, ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
理论分子量 | 51kDa |
细胞定位 | 细胞膜 |
性 状 | Liquid |
浓 度 | 1mg/ml |
免 疫 原 | KLH conjugated synthetic peptide derived from human OGFRL1: 51-150/451 |
亚 型 | IgG |
纯化方法 | affinity purified by Protein A |
缓 冲 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
保存条件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
PubMed | PubMed |
产品介绍 |
OGFRL1 is a 451 amino acid protein belonging to the opioid growth factor receptor family. OGFRL1 is ubiquitously expressed and is encoded by a gene mapping to human chromosome 6. Making up nearly 6% of the human genome, chromosome 6 contains around 1,200 genes within 170 million base pairs of sequence. Deletion of a portion of the q arm of chromosome 6 is associated with early onset intestinal cancer, suggesting the presence of a cancer susceptibility locus. Additionally, Porphyria cutanea tarda, Parkinson's disease, Stickler syndrome and a susceptibility to bipolar disorder are all associated with genes that map to chromosome 6. Tissue Specificity: Ubiquitous. Similarity: Belongs to the opioid growth factor receptor family. SWISS: Q5TC84 Gene ID: 79627 Database links: Entrez Gene: 79627 Human SwissProt: Q5TC84 Human Unigene: 648434 Human |
1、抗体溶解方法 | |
2、抗体修复方式 | |
3、常用试剂的配制 | |
4、免疫组化操作步骤 | |
5、免疫组化问题解答 | |
6、Western Blotting 操作步骤 | |
7、Western Blotting 问题解答 | |
8、关于肽链的设计 | |
9、多肽的溶解与保存 | |
10、酶标抗体效价测定程序 | |